Early neonatal treatment and immune quiescence
Early neonatal treatment and immune quiescence
批准号:
8727251
负责人:
Louise Kuhn
金额:
$93.97万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-15 至 2019-04-30
关键词:
AdultAgeAnatomyAnti-Retroviral AgentsAntibody FormationAutomobile DrivingBirthBloodBlood specimenCCR5 geneCaringCase StudyCellsChildChronicClinicalClinical ServicesClinical TrialsColorDataDevelopmentDiagnostic testsEarly treatmentEligibility DeterminationEventFecesFlow CytometryGastrointestinal tract structureHIVHIV AntibodiesHIV SeropositivityHospitalsHourHumanHuman immunodeficiency virus testImmuneImmune systemImmunityInfantInfectionInterventionIntestinesLaboratoriesLifeMaintenanceMeasuresMemoryMethodsMississippiMonitorMothersNeonatalNewborn InfantOutcomeParentsPediatric HospitalsPharmaceutical PreparationsPhenotypePopulationPositioning AttributeProcessPublic HealthQuality of lifeRecruitment ActivityRegimenRelative (related person)ReportingResearch InfrastructureRestRoleSafetySamplingScheduleServicesSiteSouth AfricaT-Cell ActivationT-LymphocyteTestingTimeTissuesViralantiretroviral therapyarmbaseclinical carecohortdesignfunctional outcomesimprovedinfant outcomeinflammatory markerinnovationmeetingsperipheral bloodpoint of careprogramspublic health relevancesuccesstransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-lasting viral reservoir in resting CD4 memory cells and other anatomic sanctuaries requires that antiretroviral therapy (ART) be continued life-long. The recent report of the infant in Mississippi who started treatment within 30
hours of birth and who has been able to maintain viral suppression off treatment raises the tantalizing possibility that establishment of the viral reservoir may be avoidable in some infants.
Limitations of this single case report necessitate urgent replication as the potential public healt benefits of the intervention are profound. We propose a single-arm clinical trial in Johannesburg, South Africa, to replicate the Mississippi case in a more robust number of infants. Our trial is designed to test whether initiation of ART within 48 hours of birth has the potential to allow the majority of HIV-infected infants to safely discontinue ART without viral rebound. The context of starting ART within hours of birth and stopping it 18 months later provides an unprecedented opportunity to elucidate mechanisms involved in the establishment and maintenance of viral reservoir. In the context of this unique trial, we will collect samples before, during and after AR cessation to investigate potential mechanisms driving the establishment of the viral reservoir. Following the exciting new findings from the Mississippi child, we hypothesize that infant immunological developmental maturity is one of the critical parameters influencing the success of early treatment. ART given at birth is not only close in time to acquisition of infection but is
given during a developmentally-critical time period when the immune system is transitioning to its mature form and is at its most quiescent. We will also recruit a carefully-selected observational cohort of infants 4-12 weeks of age initiating and continuing ART in the standard way from routine clinical services. We will investigate whether lesser CCR5 and CD2 expression on T-cells, a smaller pool of CD4 memory cells, reduced markers of T-cell activation, and larger proportions of regulatory (suppressive) T-cells (T-regs) relative to Th17 cells will be associated with more limited seeding and greater decay of the viral reservoir when ART is started at a young age. We will also investigate whether markers in infant stool samples can be used as a non-invasive method of defining relevant immune and HIV-specific parameters associated with smaller viral reservoirs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Automated Digital Imaging for Cervical Cancer Screening
-
批准号:10414907
-
项目类别:
-
资助金额:$51.12万
-
财政年份:2020
-
负责人:Louise Kuhn
-
依托单位:
Automated Digital Imaging for Cervical Cancer Screening
-
批准号:10082877
-
项目类别:
-
资助金额:$55.51万
-
财政年份:2020
-
负责人:Louise Kuhn
-
依托单位:
Automated Digital Imaging for Cervical Cancer Screening
-
批准号:10634569
-
项目类别:
-
资助金额:$51.65万
-
财政年份:2020
-
负责人:Louise Kuhn
-
依托单位:
Automated Digital Imaging for Cervical Cancer Screening
-
批准号:10210372
-
项目类别:
-
资助金额:$51.9万
-
财政年份:2020
-
负责人:Louise Kuhn
-
依托单位:
Oral microbial signatures in perinatal HIV infection
-
批准号:10197099
-
项目类别:
-
资助金额:$59.66万
-
财政年份:2018
-
负责人:Louise Kuhn
-
依托单位:
Early neonatal treatment and immune quiescence
-
批准号:9260039
-
项目类别:
-
资助金额:$95.58万
-
财政年份:2014
-
负责人:Louise Kuhn
-
依托单位:
Improving specificity of HPV Screen-and-Treat in South Africa
-
批准号:8789475
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2014
-
负责人:Louise Kuhn
-
依托单位:
Improving specificity of HPV Screen-and-Treat in South Africa
-
批准号:8929184
-
项目类别:
-
资助金额:$49.82万
-
财政年份:2014
-
负责人:Louise Kuhn
-
依托单位:
Improving specificity of HPV Screen-and-Treat in South Africa
-
批准号:9339765
-
项目类别:
-
资助金额:$54.65万
-
财政年份:2014
-
负责人:Louise Kuhn
-
依托单位:
Host epigenetic and mitochondrial function in HIV-infected children
-
批准号:8703154
-
项目类别:
-
资助金额:$71.48万
-
财政年份:2012
-
负责人:Louise Kuhn
-
依托单位:
Host epigenetic and mitochondrial function in HIV-infected children
-
批准号:8385392
-
项目类别:
-
资助金额:$79.23万
-
财政年份:2012
-
负责人:Louise Kuhn
-
依托单位:
Host epigenetic and mitochondrial function in HIV-infected children
-
批准号:9100865
-
项目类别:
-
资助金额:$68.67万
-
财政年份:2012
-
负责人:Louise Kuhn
-
依托单位:
Host epigenetic and mitochondrial function in HIV-infected children
-
批准号:8703860
-
项目类别:
-
资助金额:$9.95万
-
财政年份:2012
-
负责人:Louise Kuhn
-
依托单位:
Host epigenetic and mitochondrial function in HIV-infected children
-
批准号:8515489
-
项目类别:
-
资助金额:$71.19万
-
财政年份:2012
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:8438493
-
项目类别:
-
资助金额:$47.62万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:8059594
-
项目类别:
-
资助金额:$50.82万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:8225290
-
项目类别:
-
资助金额:$50.12万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:8124226
-
项目类别:
-
资助金额:$44.47万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:7928380
-
项目类别:
-
资助金额:$53.13万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
Treatment Options for Protease Inhibitor Exposed Children
-
批准号:8625798
-
项目类别:
-
资助金额:$48.84万
-
财政年份:2010
-
负责人:Louise Kuhn
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: